This activity is based on review articles in the journal ONCOLOGY. It is developed from an identified educational need for information about practical management issues in the practice of medical, surgical, and radiation oncology. This activity has been developed and approved under the direction of CME LLC.

CME LLC has collaborated with a team of oncology and hematology specialists to provide insight into currently unresolved treatment dilemmas. In ONCOLOGY, October 2009, these experts write about recent advances that are pertinent for oncology practice, and provide a seasoned and practical perspective that may advance patient care.

CME, 3 Credits    Nov 30, 2009

Recent trials have led to changes in the standard regimens, which now include the use of oxaliplatin (Eloxatin) for most patients with stage III colon cancer. The addition of oxaliplatin has resulted in a 23% reduction in the risk of recurrence compared with fluorouracil/leucovorin alone, with a small but statistically significant survival benefit. Unfortunately, no adequately powered trial has determined whether adjuvant chemotherapy is beneficial for stage II patients, and its use is much more controversial. Most investigators agree that adjuvant chemotherapy has some activity against stage II disease. However, its impact on progression-free and overall survival remains highly controversial.

The identification of high-risk features may define a subset of stage II patients who, as a result of their worse prognosis, may derive a greater absolute benefit from adjuvant treatment.  Because of this worse prognosis, there is growing acceptance of an informal classification system (T Stage, Lymph Node Evaluation, Lymphovascular Invasion, and Tumor Grade) which stratifies stage II patients by risk on the basis of clinical data, as a guide for deciding whether to use adjuvant therapy. Flash Updates in Stage II Colorectal Cancer: To Treat or Not to Treat, provides insights on how to make effective treatment choices.

CME, 0.5 Credits    Nov 20, 2009

This activity is based on review articles in the journal ONCOLOGY. It is developed from an identified educational need for information about practical management issues in the practice of medical, surgical, and radiation oncology. This activity has been developed and approved under the direction of CME LLC.

CME LLC has collaborated with a team of oncology and hematology specialists to provide insight into currently unresolved treatment dilemmas. In ONCOLOGY, November 2009, these experts write about recent advances that are pertinent for oncology practice, and provide a seasoned and practical perspective that may advance patient care.

CME, 3 Credits    Nov 15, 2009

This activity is based on review articles in the journal ONCOLOGY. It is developed from an identified educational need for information about practical management issues in the practice of medical, surgical, and radiation oncology. This activity has been developed and approved under the direction of CME LLC.

CME LLC has collaborated with a team of oncology and hematology specialists to provide insight into currently unresolved treatment dilemmas. In ONCOLOGY, October 2009, these experts write about recent advances that are pertinent for oncology practice, and provide a seasoned and practical perspective that may advance patient care

CME, 3 Credits    Oct 15, 2009

The 2009 Gastrointestinal Oncology Conference, the official meeting of the International Society of Gastrointestinal Oncology, will provide an educational forum for presenting and discussing the latest advances in the broad field of GI cancer research, as well as critical issues relevant to the care of persons with GI cancer.
 
The conference will feature distinguished speakers covering a broad spectrum of topics ranging from basic science to clinical therapeutics. Presenters and discussants will explore current issues and debate controversial topics. Case presentations will be given by the faculty and the audience will participate by an interactive audience response system to stimulate discussion on diagnosis and management. This program should be of interest to professionals actively engaged clinically or scientifically in all facets of GI cancer research and care.

CME, 1.75 Credits    Oct 01, 2009

The 2009 Gastrointestinal Oncology Conference, the official meeting of the International Society of Gastrointestinal Oncology, will provide an educational forum for presenting and discussing the latest advances in the broad field of GI cancer research, as well as critical issues relevant to the care of persons with GI cancer.
 
The conference will feature distinguished speakers covering a broad spectrum of topics ranging from basic science to clinical therapeutics. Presenters and discussants will explore current issues and debate controversial topics. Case presentations will be given by the faculty and the audience will participate by an interactive audience response system to stimulate discussion on diagnosis and management. This program should be of interest to professionals actively engaged clinically or scientifically in all facets of GI cancer research and care.

CME, 1 Credits    Oct 01, 2009

The prevalence of pain and inadequate analgesia in patients with cancer is well documented. Pain management is frequently necessary in cancer treatment, making it critical that those treating the cancer patient completely understand how to correctly assess the pain and determine the proper type of treatment.

CME LLC has collaborated with a team of oncology specialists in the field of pain management. In Managing Cancer Pain: A Bedside Approach, these experts discuss recent advances that are pertinent for oncology practice, and provide a seasoned and practical perspective that may advance patient care.

CME, 1 Credits    Oct 01, 2009

Since the early 1990s, postoperative adjuvant chemoradiotherapy was widely viewed as the main approach to treat patients with stage II and III rectal cancer. Over the past few years, significant efforts have shifted towards developing neoadjuvant approaches, which combine chemotherapy with radiotherapy prior to surgical resection.

CME LLC has collaborated with a team of oncology and hematology specialists to provide insight into currently unresolved treatment dilemmas. In "Controversies in the Management of Rectal Cancer," these experts write about recent advances that are pertinent for oncology practice, and provide a seasoned and practical perspective that may advance patient care.

CME, 2 Credits    Sep 15, 2009

This activity is based on review articles in the journal ONCOLOGY. It is developed from an identified educational need for information about practical management issues in the practice of medical, surgical, and radiation oncology. This activity has been developed and approved under the direction of CME LLC.

CME, 3 Credits    Sep 15, 2009

The biggest breakthrough in the management of advanced colorectal cancer over the last decade has been the ability of medical oncologists, using modern cytotoxic and biologic, targeted agents, to convert inoperable liver disease to resectable disease. Five-year survival rates for the initially unresectable treated with neoadjuvant chemotherapy are approaching the 5-year survival rates of those cancer patients with initially resectable disease. Neoadjuvant/perioperative chemotherapy is largely available at university-based medical centers where a multidisciplinary team (medical oncologist, surgeon, and radiologist) takes care of patients with initially unresectable and resectable disease.

CME LLC has collaborated with a team of oncology and hematology specialists to provide insight into currently unresolved treatment dilemmas. In E-Updates in Liver-Limited Disease, these experts write about recent advances that are pertinent for oncology practice, and provide a reasoned and practical perspective that may advance patient care.

CME, 1.5 Credits    Sep 15, 2009